Medy-Tox Inc Market Cap ($279.09 Million)
Market Cap & Net Worth: Medy-Tox Inc (086900)
Medy-Tox Inc market cap. Medy-Tox Inc (KQ:086900) has a market capitalization of $279.09 Million (₩411.83 Billion) as of November 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #14911 globally and #484 in its home market, demonstrating a -7.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medy-Tox Inc's stock price ₩62600.00 by its total outstanding shares 6578751 (6.58 Million). Also see cash efficiency ratio of Medy-Tox Inc for how efficiently the company converts equity into cash flow.
Medy-Tox Inc Market Cap History (2015–2026)
Medy-Tox Inc market cap history from 2015 to 2026. Data shows change from $1.78 Billion to $279.09 Million (-14.09% CAGR). Check Medy-Tox Inc share price for real-time trading data and today's change.
Index Memberships
Medy-Tox Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$207.23 Billion | 0.13% | #151 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$207.23 Billion | 0.13% | #151 of 1384 |
Weight: Medy-Tox Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Medy-Tox Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medy-Tox Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Medy-Tox Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Medy-Tox Inc's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.03x
Medy-Tox Inc's market cap is 0.03 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.78 Billion | $88.51 Billion | $42.29 Billion | 0.02x | 0.04x |
| 2016 | $1.25 Billion | $133.26 Billion | $59.23 Billion | 0.01x | 0.02x |
| 2017 | $1.70 Billion | $181.24 Billion | $70.11 Billion | 0.01x | 0.02x |
| 2018 | $2.09 Billion | $205.44 Billion | $69.96 Billion | 0.01x | 0.03x |
| 2019 | $1.12 Billion | $205.90 Billion | $26.21 Billion | 0.01x | 0.04x |
| 2020 | $689.65 Million | $140.83 Billion | -$29.58 Billion | 0.00x | N/A |
| 2021 | $599.60 Million | $184.87 Billion | $94.15 Billion | 0.00x | 0.01x |
| 2022 | $565.00 Million | $195.10 Billion | $37.01 Billion | 0.00x | 0.02x |
| 2023 | $1.07 Billion | $221.12 Billion | $9.76 Billion | 0.00x | 0.11x |
| 2024 | $556.40 Million | $228.62 Billion | $16.95 Billion | 0.00x | 0.03x |
Competitor Companies of 086900 by Market Capitalization
Companies near Medy-Tox Inc in the global market cap rankings as of November 5, 2026. Also see Medy-Tox Inc total assets for a full breakdown of the balance sheet.
Key companies related to Medy-Tox Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Medy-Tox Inc (2015–2026)
Market capitalization of Medy-Tox Inc from 2015 to today. Between 2015 and today, Medy-Tox Inc's market cap moved from $1.78 Billion to $ 279.09 Million, with a yearly change of -14.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩279.09 Million | -48.18% |
| 2025 | ₩538.57 Million | -3.21% |
| 2024 | ₩556.40 Million | -47.92% |
| 2023 | ₩1.07 Billion | +89.11% |
| 2022 | ₩565.00 Million | -5.77% |
| 2021 | ₩599.60 Million | -13.06% |
| 2020 | ₩689.65 Million | -38.63% |
| 2019 | ₩1.12 Billion | -46.25% |
| 2018 | ₩2.09 Billion | +22.91% |
| 2017 | ₩1.70 Billion | +36.57% |
| 2016 | ₩1.25 Billion | -30.09% |
| 2015 | ₩1.78 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Medy-Tox Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $279.09 Million USD |
| MoneyControl | $279.09 Million USD |
| MarketWatch | $279.09 Million USD |
| marketcap.company | $279.09 Million USD |
| Reuters | $279.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medy-Tox Inc
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and … Read more